← Back to Screener
Bausch + Lomb Corporation (BLCO)
Price$16.59
Favorite Metrics
Price vs S&P 500 (26W)10.77%
Price vs S&P 500 (4W)-0.45%
Market Capitalization$5.98B
All Metrics
P/CF (Annual)21.13x
Book Value / Share (Quarterly)$18.20
P/TBV (Annual)1.91x
Revenue Growth (3Y)10.62%
Cash Flow / Share (Quarterly)$-0.19
Price vs S&P 500 (YTD)-3.81%
Gross Margin (TTM)59.81%
Net Profit Margin (TTM)-7.06%
EPS (TTM)$-1.02
10-Day Avg Trading Volume0.34M
EPS Excl Extra (TTM)$-1.02
Revenue Growth (5Y)8.38%
EPS (Annual)$-1.02
ROI (Annual)-3.12%
Gross Margin (Annual)59.81%
Net Profit Margin (5Y Avg)-2.99%
Cash / Share (Quarterly)$1.08
Revenue Growth QoQ (YoY)9.77%
ROA (Last FY)-2.57%
Revenue Growth TTM (YoY)6.47%
EBITD / Share (TTM)$1.03
ROE (5Y Avg)-2.45%
Operating Margin (TTM)2.10%
Cash Flow / Share (Annual)$-0.19
P/B Ratio0.93x
P/B Ratio (Quarterly)0.94x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)2.09x
Net Interest Coverage (TTM)0.25x
ROA (TTM)-2.61%
EV / EBITDA (TTM)29.26x
EPS Incl Extra (Annual)$-1.02
Current Ratio (Annual)1.55x
Quick Ratio (Quarterly)0.84x
3-Month Avg Trading Volume0.39M
52-Week Price Return37.80%
EV / Free Cash Flow (Annual)34.57x
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$8.94
P/S Ratio (Annual)1.17x
Asset Turnover (Annual)0.36x
52-Week High$18.91
Operating Margin (5Y Avg)4.57%
EPS Excl Extra (Annual)$-1.02
CapEx CAGR (5Y)6.65%
26-Week Price Return14.75%
Quick Ratio (Annual)0.84x
13-Week Price Return-3.54%
Total Debt / Equity (Annual)0.79x
Current Ratio (Quarterly)1.55x
Enterprise Value$10,679.891
Revenue / Share Growth (5Y)8.14%
Asset Turnover (TTM)0.37x
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)2.04x
Pretax Margin (Annual)-6.21%
Cash / Share (Annual)$1.08
3-Month Return Std Dev31.61%
Gross Margin (5Y Avg)60.37%
Net Income / Employee (TTM)$-0
EBITDA CAGR (5Y)-8.94%
EBITDA Interim CAGR (5Y)1.11%
ROE (Last FY)-5.58%
Net Interest Coverage (Annual)0.25x
EPS Basic Excl Extra (Annual)$-1.02
P/FCF (TTM)48.63x
Receivables Turnover (TTM)4.54x
EV / Free Cash Flow (TTM)639.79x
Total Debt / Equity (Quarterly)0.79x
EPS Incl Extra (TTM)$-1.02
Receivables Turnover (Annual)4.54x
ROI (TTM)-3.16%
P/S Ratio (TTM)1.17x
Pretax Margin (5Y Avg)-0.94%
Revenue / Share (Annual)$14.42
Tangible BV / Share (Annual)$8.94
Forward P/E21.75x
Price vs S&P 500 (52W)7.97%
Year-to-Date Return-1.17%
5-Day Price Return2.43%
EPS Normalized (Annual)$-1.02
ROA (5Y Avg)-1.02%
Net Profit Margin (Annual)-7.06%
Month-to-Date Return6.16%
Cash Flow / Share (TTM)$0.46
EBITD / Share (Annual)$1.03
Operating Margin (Annual)2.10%
LT Debt / Equity (Annual)0.78x
P/CF (TTM)21.13x
ROI (5Y Avg)-1.24%
LT Debt / Equity (Quarterly)0.78x
EPS Basic Excl Extra (TTM)$-1.02
P/TBV (Quarterly)1.91x
P/B Ratio (Annual)0.94x
Inventory Turnover (TTM)2.04x
Pretax Margin (TTM)-6.21%
Book Value / Share (Annual)$18.20
Price vs S&P 500 (13W)-4.23%
Beta0.66x
P/FCF (Annual)35.18x
Revenue / Share (TTM)$14.39
ROE (TTM)-5.61%
52-Week Low$10.45
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
3.63
3.63
3.58
3.58
Industry Peers — Ophthalmic Goods(5)
| Symbol | P/E Ratio (Annual) | ROE (TTM) | Revenue Growth (5Y) | Indicated Dividend Yield (Annual) | Price |
|---|---|---|---|---|---|
BLCOBausch + Lomb Corporation | — | -5.61% | 8.38% | — | $16.59 |
COOThe Cooper Companies, Inc. Common Stock | 36.30x | 4.83% | 10.98% | 0.02% | $69.38 |
WRBYWarby Parker Inc. | 1768.44x | 0.45% | 17.24% | — | $23.17 |
EYENational Vision Holdings, Inc. Common Stock | 67.55x | 3.47% | 3.03% | — | $24.87 |
STAAStaar Surgical Co | — | -23.24% | 7.93% | — | $24.62 |
RXSTRxSight, Inc. Common Stock | — | -14.05% | 55.73% | — | $7.38 |
About
Bausch & Lomb is one of the largest US vision care companies, operating three segments: vision care (contact lenses with ~10% market share, plus brands like Biotrue and Lumify), surgical devices for ophthalmic procedures, and ophthalmic pharmaceuticals. The company was spun off from Bausch Health in 2022 and maintains the industry's largest portfolio of eye care prescriptions, with over 100 products. This diversified portfolio across consumer, surgical, and pharmaceutical markets provides exposure to multiple customer segments within ophthalmology.